NUVB — Nuvation Bio Inc.

Nuvation Bio Inc. Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $83.2 million, with $18.5 million from Iptrozy net U.S. product revenue, marking an 18% increase from the previous quarter.
• New Patient Starts: Approximately 200 new patients treated with Iptrozy for the third consecutive quarter, totaling over 600 since launch.
• Collaboration and License Revenue: $64.7 million, including a $60 million upfront payment from Eisai.
• Operating Expenses: Totaled $73.5 million, with R&D expenses at $35 million and SG&A expenses at $38.3 million.
• Cash Position: Ended the quarter with $533.7 million in cash, cash equivalents, and marketable securities.

2. Strategic Updates and Business Highlights

• Iptrozy Launch: Focused on building a successful commercial launch in ROS1-positive non-small cell lung cancer (NSCLC). Notable progress includes a shift towards first-line treatment, with over 50% of new patients being TKI-naive.
• Clinical Data: Iptrozy demonstrated a median duration of response of 50 months in TKI-naive patients and a 66% intracranial response rate in the second-line setting.
• NCCN Guidelines: Iptrozy was added to the latest NCCN CNS guidelines, enhancing its positioning as a treatment option for patients with brain metastases.
• Safusitinib Development: Ongoing Phase 3 SIGMA study for IDH1-mutant glioma shows promise, with plans to expand into Japan following the acquisition of rights from Daiichi Sankyo.

3. Forward Guidance and Outlook

• Revenue Growth: Continued expectation of revenue stacking as the proportion of first-line patients increases. The company anticipates maintaining or exceeding consensus revenue estimates for the year.
• Patient Identification Initiatives: Plans to enhance community testing and education to increase the diagnosis and treatment of ROS1-positive patients.
• Long-Term Value Creation: Focus on building a durable patient base and expanding market presence through strategic partnerships and educational initiatives.

4. Bad News, Challenges, or Points of Concern

• Discontinuation Rates: Discontinuations primarily driven by disease progression in later-line patients, which may introduce variability in near-term revenue.
• Testing Rates: Lower testing rates in community settings compared to academic centers, which could hinder patient identification and treatment initiation.
• Competitive Landscape: Emerging competitors presenting data that may influence treatment decisions and market dynamics, particularly in the second-line setting.

5. Notable Q&A Insights

• Patient Mix Dynamics: The increase in first-line patients is attributed to improved diagnosis and awareness, but the drop-off of late-line patients is affecting overall new patient start metrics.
• CNS Profile Importance: The NCCN CNS guideline inclusion is expected to positively influence treatment decisions, particularly for patients with brain metastases.
• Salesforce and Market Education: The company is actively addressing community testing gaps and enhancing educational initiatives to drive adoption and awareness among oncologists.
• Future Metrics Focus: Moving forward, the emphasis will shift from new patient starts to metrics such as the proportion of first-line patients, durability of treatment, and gross-to-net revenue dynamics.

Overall, Nuvation Bio is experiencing strong momentum with Iptrozy's launch, supported by encouraging clinical data and strategic initiatives, while facing challenges related to patient discontinuation and competitive pressures.